The pharmaceuticals generic industry is a significant player in the global drug market. Generic drugs, which contain the same chemical substance as their patented counterparts, are sold at more affordable prices once the patents for the original drugs expire. This affordability has led to the vast popularity of generic drugs. As per the Center for Justice and Democracy at New York Law School, a staggering 80% of all prescribed drugs are generic, and they are the preferred choice 94% of the time when available. Companies in this sector, such as Zoetis, Inc., Allergan plc, and Mylan N.V., must demonstrate to the FDA that their products are effective substitutes for the original drugs.
Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA) - Annualized Return + 64%
Two of the standout companies in this industry are:
The pharmaceuticals generic industry has a diverse range of companies in terms of market capitalization. On average, the market cap across the theme is $12.3B. ZOETIS (ZTS) leads the pack with a valuation of $86.1B, while the smallest player, ACUR, is valued at just 39.6K.
Price Movements: Highs and Lows
The industry has seen varied price movements over different periods:
Some notable price movements include:
Trading volumes provide insights into the liquidity and investor interest in stocks. For the pharmaceuticals generic theme:
A notable volume trend was observed for Dr. Reddy's Laboratories, which saw its stock volume increase consecutively for five days, with daily gains ranging from 92% to 94%.
Fundamental Analysis Ratings
Investors often rely on fundamental analysis ratings to gauge the health and potential of companies. For the pharmaceuticals generic industry, the ratings range from 1 (best) to 100 (worst). The specific average ratings for companies within this theme are not provided in the text.
In conclusion, the pharmaceuticals generic industry has shown resilience and growth, with an average gain of 10.89% in the past month. With major players like ZOETIS and Teva leading the way, the industry continues to be a significant contributor to the global pharmaceutical market.
TEVA - On August 28, 2023, TEVA's Momentum Indicator crossed the pivotal 0 mark, hinting at a possible upward trajectory for the stock. Investors might contemplate acquiring the stock or considering call options. Historical data from Tickeron's A.I.dvisor, analyzing 78 analogous events, reveals that the stock ascended in 58 instances post such a shift. This places the likelihood of an upward move at an impressive 74%.
RDY - On August 24, 2023, RDY's 10-day RSI Oscillator transitioned from the overbought region, suggesting a potential shift from an upward to a downward trend. Investors might consider offloading the stock or exploring put options. Historical analysis by Tickeron's A.I.dvisor, examining 36 similar transitions, showed that in 21 instances, the stock declined in subsequent days. This data indicates a 58% probability of a downward movement.
TARO - On August 25, 2023, TARO's 10-day Moving Average made a bullish crossover above its 50-day counterpart. This suggests a potential upward momentum and may serve as a buying cue for investors. Historical data reveals that in 8 out of 14 previous occurrences of such a crossover, TARO's stock sustained its rise over the subsequent month. This presents a 57% likelihood of the stock maintaining its upward trajectory.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TEVA declined for three days, in of 336 cases, the price declined further within the following month. The odds of a continued downward trend are .
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
TEVA broke above its upper Bollinger Band on September 13, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on September 11, 2023. You may want to consider a long position or call options on TEVA as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TEVA just turned positive on September 13, 2023. Looking at past instances where TEVA's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for TEVA moved above the 200-day moving average on September 11, 2023. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 161 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.636) is normal, around the industry mean (85.187). P/E Ratio (22.624) is within average values for comparable stocks, (58.563). TEVA's Projected Growth (PEG Ratio) (10.500) is very high in comparison to the industry average of (3.400). TEVA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (0.764) is also within normal values, averaging (61.422).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients
A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with VTRS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then VTRS could also see price increases.